Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History INVA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics INVA

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield 5.03 %
Consecutive Years 0
Forward Annual Dividend 1.00 USD
Consistent Years 0
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date 08.09.2015

Innoviva Inc

INVA
Current price
19.88 USD -0.29 USD (-1.44%)
Last closed 20.25 USD
ISIN US45781M1018
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 1 196 495 232 USD
Yield for 12 month +16.19 %
1Y
3Y
5Y
10Y
15Y
INVA
21.11.2021 - 28.11.2021

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline), a tetracycline class antibacterial for the treatment of complicated intra-abdominal infections in adults; XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia; and ZEVTERA, a cephalosporin antibacterial for the treatment of adult patients with staphylococcus aureus bloodstream infections, adult patients with acute bacterial skin and skin structure infections, and adult and pediatric patients with community-acquired bacterial pneumonia. Its development pipeline includes Zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California. Address: 1350 Old Bayshore Highway, Burlingame, CA, United States, 94010

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

55.00 USD

P/E Ratio

Dividend Yield

Financials INVA

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures INVA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+358 711 000 USD

Last Year

+310 463 000 USD

Current Quarter

+88 632 000 USD

Last Quarter

+91 806 000 USD

Current Year

+322 113 000 USD

Last Year

+261 065 000 USD

Current Quarter

+79 790 000 USD

Last Quarter

+78 077 000 USD
EBITDA 215 754 000 USD
Operating Margin TTM 47.02 %
Price to Earnings
Return On Assets TTM 9.40 %
PEG Ratio 0.24
Return On Equity TTM -8.84 %
Wall Street Target Price 55.00 USD
Revenue TTM 369 844 000 USD
Book Value 10.31 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 14.40 %
Dividend Yield
Gross Profit TTM 328 424 000 USD
Earnings per share -0.95 USD
Diluted Eps TTM -0.95 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY -63.00 %
Profit Margin -16.15 %

Stock Valuation INVA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 3.27
Price Sales TTM 3.24
Enterprise Value EBITDA 1 773.53
Price Book MRQ 1.86

Technical Indicators INVA

For 52 Weeks

16.67 USD 22.00 USD
50 Day MA 19.72 USD
Shares Short Prior Month 9 646 664
200 Day MA 18.83 USD
Short Ratio 10.42
Shares Short 10 229 756
Short Percent 21.25 %